to the point that methods of manipulating these factors are under development. One such technology is genetic modification of vein grafts just before arterial bypass to impair IH. Gene therapy has been shown to be successful at reducing IH after arterial injury in both small and large animals, as well as reducing IH resulting from transplantrelated vasculopathy. 2 Similar approaches may be efficacious in preventing vein graft IH.
Nitric oxide (NO) has a number of vasoprotective properties that include the ability to inhibit platelet adherence 3 and leukocyte chemotaxis, 4 inhibit vascular smooth muscle cell proliferation 5 and migration, 6, 7 and promote endothelial cell growth 8 and survival. 9, 10 These properties serve as the underlying bases for the development of NO synthase (NOS) gene therapy for vascular disease. To date, all three NOS isoforms have been transferred into blood vessels for various vascular disorders. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] We have shown that adenoviral gene transfer of the human inducible NOS (iNOS) gene to both injured rat and pig arteries dramatically inhibit IH 14 and also prevented transplant-related vasculopathy in rats after allogeneic aortic transplantation. 15 However, the effect of iNOS gene transfer on vein grafts has not been evaluated. Given the vasoprotective properties of NO and the efficacy of NOS-based gene transfer to the arterial wall, the aim of this study was to Vein graft failure in the treatment of cardiovascular disease remains a significant clinical and economic concern. 1 Over the last decade, our understanding of the biology of the vessel wall and of the cellular and humoral influences that contribute to the pathophysiologic condition of vein graft intimal hyperplasia (IH) has progressed determine whether adenoviral iNOS gene transfer would be similarly beneficial in inhibiting vein graft IH.
MATERIAL AND METHODS

Adenoviral vectors.
A first-generation E1-and E3deleted adenoviral vector carrying either the human iNOS cDNA 22 (AdiNOS) or β-galactosidase cDNA (AdlacZ) was constructed as previously described. 14, 15 The titer of AdiNOS was ~1 × 10 11 particles/mL (~10 9 plaque-forming units per milliliter [pfu/mL]) and AdlacZ was ~1 × 10 13 particles/mL (~10 11 pfu/mL).
Animals and surgical procedure. All animal procedures were performed by use of aseptic technique in accordance with the Institutional Animal Care and Use Committee of the University of Pittsburgh. Domestic juvenile castrated male pigs (Walter Whippo, Enon Valley, Pa) weighing 12 to 15 kg were anesthetized with intravenous sodium pentobarbital and inhalational isoflurane and nitrous oxide. Antibiotic prophylaxis was provided with one dose of cefazolin before and after operation. Bilateral carotid arteries and internal jugular (IJ) veins were exposed through a midline neck incision. A 6-cm segment of IJ vein was harvested, rinsed in normal saline solution, and placed into 1 mL of Optimem (Gibco BRL, Rockville, Md) containing 1 × 10 11 particles of either AdiNOS or AdlacZ. After 30 minutes incubation at room temperature, the vein was rinsed, and a 1.0-cm ring segment of vein was placed in organ culture media. Five minutes before carotid arterial occlusion, the animal received heparin (100 U/kg) intravenously. A 2-cm segment of the carotid artery was resected, and the treated vein graft was placed into the arterial circulation as an interposition graft. End-to-end anastomoses were performed at the proximal and distal ends with 7-0 nylon (Surgilene; USSC, Exeter, NH). Excellent size match between the vein grafts and the carotid arteries were noted. The neck incisions were closed with absorbable suture (Polysorb; USSC).
Ex vivo vein segment organ culture. One-centimeter vein segments were cultured in Dulbecco modified Eagle's medium (low glucose)/Ham's F12 (1:1 vol:vol) (BioWhittaker, Walkersville, Md) supplemented with 10% fetal bovine serum, penicillin 100 U/mL, streptomycin 100 µg/mL, and L-glutamine 4 mmol/L in a 37°C, 95% air/5% CO 2 incubator. Medium was changed daily, and the supernatant was assayed for nitrite, a stable breakdown product of NO, by use of the Griess reaction. 23 Nitrite production was normalized to tissue sample weight and reported as nanomoles per gram.
Tissue processing. Vein grafts were collected at 3 (n = 4), 7 (n = 4), or 21 (n = 8) days after bypass. Animals were anesthetized, and the vein grafts were exposed through the prior midline incision. The proximal carotid artery was ligated 3 cm from the proximal anastomosis. The distal carotid artery was transected, and 2% paraformaldehyde was infused to distend the graft, which was then removed and fixed in 2% paraformaldehyde for 2 hours at 4°C followed by 30% sucrose at 4°C overnight. Vessels were cut into 0.5-cm sections and snap-frozen in liquid nitrogen. Small segments JOURNAL OF VASCULAR SURGERY Volume 34, Number 1
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of small bowel were also harvested, fixed, frozen, and cut to serve as positive controls for immunohistochemical staining.
X-gal staining for β-galactosidase activity. Frozen sections of vein graft (7 µm) were washed twice in MgCl 2 (1 mmol/L) for 15 minutes and stained with X-gal (Sigma Chemical Co, St Louis, Mo) at 37°C overnight, and images were obtained by light microscopy (Nikon light microscope; Nikon, Melville, NY) to quantify positive blue-staining cells.
Immunohistochemistry. For immunofluorescent staining, vein sections were rinsed in phosphate-buffered saline solution (PBS) followed by a bovine serum albumin (BSA) mixture (100 mL PBS + 0.15 g glycine + 0.5 g BSA), blocked with purified goat immunoglobulin G (50 mg/mL; Sigma Chemical Co), and then incubated with a mouse monoclonal anti-Ki67 antibody (1:100; Vector Labs, Burlingame, Calif) for 1 hour. The sections were washed and incubated with the secondary goat antimouse Cy3-labeled antibody (1:3000; Jackson ImmunoResearch Laboratories, West Grove, Pa) for 1 hour. Nuclei were stained with Hoechst 33325 (Sigma Chemical Co) for 30 seconds. Images were collected by use of a high NA planapo objective at original magnification × 40, an Olympus Provis microscope (Olympus, Tokyo, Japan), and Optimus software (Media Cybernetics, Silver Spring, Md).
For immunoperoxidase staining, tissue sections were rinsed in PBS, blocked with purified goat immunoglobulin G (Sigma Chemical Co) for 30 minutes and then incubated with the primary antibody for 1 hour (CD45 1:100, BD Pharmingen, San Diego, Calif; ED1 1:1000, Serotec, Oxford, United Kingdom; myeloperoxidase 1:300, Dako, Carpenteria, Calif). Sections were incubated with a biotinylated rabbit antimouse or mouse antirabbit secondary antibody (1:1000 Pierce, Rockford, Ill) for 1 hour and exposed to streptavidin-horseradish peroxidase (1:2000; Zymax, San Francisco, Calif) for 30 minutes followed by diaminobenzidine (Innovex, Richmond, Calif) for 3 minutes. For the contrast to be enhanced, sections were counterstained with hematoxylin. Images were collected with light microscopy.
Quantitative and morphometric analyses. Crosssectional intimal and medial areas within the vein grafts were measured by use of Optimus software. Five different regions of the graft were examined, including the distal anastomosis, distal middle of the graft, mid-graft, proximal middle of the graft, and the proximal anastomosis (Fig 1) . Proliferating cells within the media and intima of the vein graft were quantified by use of Optimus software. Images of cells expressing Ki67 were obtained, and a mask was generated. The cell profiles were detected by use of nuclear Hoescht staining, and an additional mask was generated. The two binary images were compared by use of an "AND" statement, and positive profiles were extracted. This method calculated the number of Ki67-positive cel-lular profiles, which was then compared with the total cell number in the field as determined by the Hoescht-stained image. Five random fields per section were counted for each graft region.
Statistical analysis. Results are expressed as mean ± SEM. Differences between multiple groups were analyzed by use of one-way analysis of variance with the Student-Newman-Keuls post hoc test for all pairwise comparisons. Differences between two groups were analyzed with the Student t test (SigmaStat; SPSS, Chicago, Ill). Statistical significance was assumed when P < .05.
RESULTS
Adenoviral gene transfer of β-galactosidase to porcine vein grafts results in transgene expression
throughout the vessel wall. Porcine IJ vein grafts transduced with AdlacZ expressed high levels (approximately 50%) of β-galactosidase in the media and to a lesser extent the adventitia of the vessel wall 3 days after infection and implantation as demonstrated by X-gal staining (Fig 2, A) . By 7 days, the expression was reduced but still detectable in all samples (Fig 2, B) . Vein grafts collected 21 days after bypass showed very little if any staining with X-gal (Fig 2, C) . The expression of β-galactosidase in the vein grafts should mirror iNOS expression because a cytomegalovirus promoter controls both cDNAs within the adenoviral constructs, and no posttranslational regulation beyond substrate requirements exists for either gene.
Adenoviral iNOS gene transfer to porcine vein grafts results in significant NO synthesis. After infec- tion of the porcine IJ veins with either AdiNOS or AdlacZ, segments of each vein were maintained in ex vivo organ culture. The cultured segments infected with AdiNOS produced ~5 times more NO, as measured by supernatant nitrite, than segments infected with AdlacZ (P = .00001) ( Fig 3) . These results indicate that AdiNOS infection of vein grafts resulted in functional iNOS expression.
Infection of porcine vein grafts with either AdlacZ or AdiNOS results in minimal inflammation of the vessel wall. The vein grafts were examined for neutrophil, macrophage, and lymphocyte infiltration to determine whether the adenoviral vector or either gene product induced inflammation. With immunoperoxidase staining against myeloperoxidase for neutrophils (Fig 4,  A) , ED1 for macrophages (Fig 4, B) , and CD45 for lymphocytes (Fig 4, C) , vessels infected with either AdlacZ or AdiNOS demonstrated minimal inflammatory infiltrate in the media and neointima (Fig 4) . Three days after infection, there was a slight increase in neutrophil and macrophage infiltration of the adventitia (Fig 4, A and B) in both AdlacZ-and AdiNOS-treated grafts as compared with grafts examined at 7 days, but the level of inflammation was very low and insignificant for both time points. At both 3 and 7 days, few lymphocytes were detected (Fig 4, C) . Porcine small bowel was stained for the presence of these three markers as a positive control (Fig 4) . iNOS gene transfer to vein grafts inhibits cellular proliferation. Grafts were stained for Ki67 to determine the effect of augmented NO synthesis on cellular proliferation in vein grafts. At both 3 and 7 day time points, vessels infected with AdiNOS ( Fig 5, B and D) qualitatively appeared to possess fewer Ki67-positive cells as compared with those infected with AdlacZ ( Fig 5, A and C) . Quantitatively, at 3 days after bypass, iNOS gene transfer reduced cellular proliferation by 41% versus controltreated grafts (P = .000004, Fig 6, A) . At 7 days, proliferation in AdiNOS-treated grafts was reduced 32% (P = .0001, Fig 6, C) . When different regions of the vein graft were examined, iNOS gene transfer had the most pronounced antiproliferative effect (65% reduction, P = .0005) on the distal anastomosis at 3 days after bypass ( Fig  6, B) , whereas both proximal and distal sites were equally affected at 7 days (Fig 6, D) .
iNOS gene transfer to vein grafts significantly reduced IH. Although iNOS gene transfer to vein grafts in pigs clearly inhibited cellular proliferation throughout the vessel wall, it was necessary to determine how this would impact IH and medial remodeling within the graft. At both early and late time points after gene trans- fer and implantation, grafts treated with AdiNOS exhibited a more than 30% reduction in IH as compared with AdlacZ-treated grafts (Fig 7, Table) . At 7 days, iNOS gene transfer reduced the intimal/medial area ratio (I/M) by 36% versus grafts infected with AdlacZ (0.25 ± 0.03 vs 0.39 ± 0.04, respectively, P = .009) (Fig 8, A) . By 21 days after bypass, iNOS gene transfer was still associated with a 30% reduction in neointima formation (0.47 ± 0.03 vs 0.67 ± 0.05, respectively, P = .007) ( Fig  8, C) . Given that the vein graft wall was still thin at 3 days, accurate quantification of intima and media areas JOURNAL OF VASCULAR SURGERY Volume 34, Number 1
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was not possible at that time point but early differences were already visually evident (Fig 7) . Measurements of media areas at all time points did not reveal any significant differences between AdiNOS-or AdlacZ-treated grafts (7 days: AdiNOS 2813 ± 330 vs AdlacZ 2583 ± 219 [P = NS]; 21 days: AdiNOS 3675 ± 180 vs AdlacZ 3368 ± 160 [P = NS]).
Analysis of different regions along the vein graft revealed regional variations in the antiproliferative effects of NO. At 7 days, the greatest reduction in IH was measured at the distal anastomosis in AdiNOS-infected vein grafts as compared with AdlacZ-infected grafts (Fig 8, B) . This finding was also observed at 21 days with a statistically significant reduction in the I/M at the distal anastomosis (AdiNOS 0.43 ± 0.02 vs AdlacZ 0.59 ± 0.05 [P = .01]) (Fig 8,D) .
DISCUSSION
The development of IH within vein grafts is a significant problem that limits the clinical efficacy of bypass procedures. For this reason, we sought to evaluate the role of iNOS gene transfer for inhibiting IH in porcine vein grafts. In this study, adenoviral gene transfer into porcine IJ vein grafts was associated with minimal inflammatory changes. Expression of iNOS in these vein grafts reduced total cellular proliferation by more than 30% within the vein graft, and this translated into a similar reduction in IH up to 21 days after gene transfer and bypass. Interestingly, the antiproliferative effect of iNOS gene transfer appeared to be more pronounced at the distal anastomosis. Although a significant reduction in neointima formation was observed, medial hypertrophy and remodeling was unaffected. These results indicate that iNOS gene transfer successfully inhibits IH in porcine vein grafts without impairing normal adaptive medial remodeling.
NOS gene therapy has been used to limit IH in a number of models of vascular disease. [11] [12] [13] [14] [15] [17] [18] [19] [20] [21] 24, 25 We JOURNAL OF VASCULAR SURGERY Volume 34, Number 1
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have demonstrated effective reduction in neointima formation after arterial injury from direct trauma, as well as from immune-mediated injury seen in transplant vasculopathy. 14, 15 The success of NOS gene transfer in inhibiting vein graft IH is due to the vasoprotective properties of NO that include inhibitory effects on platelets, 3 leukocytes, 4 and smooth muscle cells (SMCs), [5] [6] [7] and protective effects on endothelial cells. [8] [9] [10] The altered mechanical stresses that veins used as arterial conduits are subjected to stimulate the release of growth factors such as basic fibroblast growth factor, platelet-derived growth factor, and transforming growth factor-β, that provide the mitogenic and chemotactic drive for neointima formation. 26, 27 Furthermore, it has been reported that vein grafts placed into the arterial circulation express lower functional levels of endothelial NOS (eNOS) and NO [28] [29] [30] as a result of endothelial dysfunction or loss. Reduced NO synthesis may underlie the propensity of vein grafts to development of IH. Therefore the use of NOS gene transfer to restore and augment NO production is logical.
Early studies investigating the role of NO in vein graft IH used L-arginine supplementation in rabbit carotid artery bypass grafts with external jugular vein. 31 Davies et al 31 reported a 26.6% reduction in intimal area/intimal area + medial area at the proximal anastomosis and no reduction at the distal anastomosis in animals receiving 
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L-arginine. Our data demonstrated a greater reduction of IH at the distal anastomosis with iNOS gene transfer. An explanation for these differences may be related to the animal species used in these experiments. We propose that platelet activation plays a very important role in distal anastomotic IH. Rodents are well known to have a lesser platelet response to vascular manipulation than human beings and larger animals such as pigs. The difference between the proximal and distal anastomoses may be related to platelet activation on passage through and aggregation at the proximal anastomosis with recruitment and enhanced adherence of platelets at the distal anastomosis with increased local release of mitogens and chemotactic factors. 32 The ability of NO to inhibit platelet adherence and activation 3 may explain the greater therapeutic effectiveness of iNOS gene transfer at that site in pigs undergoing carotid artery bypass. Another possible explanation for our data may be related to the bioreactivity of NO. NO has a short half-life in the circulation, but a higher local concentration of NO may be present at the distal portion of the graft because NO released from the proximal graft could bind circulating proteins to form nitrosothiols. 33, 34 These nitrosothiols may then release NO downstream, generating a local environment with a higher NO concentration at the distal region of the graft. More recently, Matsumoto et al 18 delivered eNOS to canine femoral vein grafts under conditions of poor runoff and showed that intimal thickness was reduced in eNOS treated grafts as compared with buffer-treated control grafts. Our results indicate that iNOS delivered by an adenoviral vector effectively reduces vein graft IH. The iNOS has the theoretical advantage of providing sustained, high level NO production that is not achievable with eNOS or the neuronal NOS isoform, which may allow therapeutic efficacy with much lower levels of gene transfer efficiency. Resolution of this debate will necessitate a study directly comparing these isoforms.
Another important physiologic change that vein grafts undergo is arterialization, characterized by medial hypertrophy. 35 The media of a vein is thin compared with that of an artery. Impairment of the normal arterialization process that occurs when a vein is exposed to pulsatile, high-pressure flow in the arterial circulation may render a vein graft more susceptible to aneurysm formation and graft rupture. Genetic engineering of vein grafts to resist IH should not interfere with this remodeling process. In porcine vein grafts treated with AdiNOS, medial hypertrophy still occurred and did not significantly differ from control-treated grafts. Although iNOS gene transfer reduced proliferative activity throughout all layers of the vein graft wall, there appeared to be a preferential effect on neointimal growth. The mechanism of this selective action of NO is not clear. Although X-gal staining of AdlacZ-treated veins revealed transgene expression in all layers of the vessel wall, a greater distribution of transduced cells was found toward the vessel lumen. NO can also inhibit SMC migration, which is necessary for IH and may contribute to the preferential effect on neointima formation that we detected.
IH in vein grafts is an ongoing process that continues for years. Our studies only follow the process up to 21 days. Longer-duration studies clearly need to be performed, but we are encouraged by our results that the protective effect of adenoviral-mediated iNOS gene transfer may be durable in spite of limited transgene expression. Early endothelial dysfunction and platelet activation are the dominant stimuli for SMC migration and proliferation in vein grafts. Because peak SMC proliferative activity occurs in the first week after bypass, 36 blocking this process early may be sufficient to inhibit intimal growth long-term. We and others have shown that NO is pro-proliferative for endothelial cells and inhibits platelet activation. 37 By protecting the endothelium and blocking platelet activity, iNOS gene transfer may prevent the whole mitogenic cascade that results in vein graft IH from occurring.
A criticism of adenovirus-based gene therapies has been the potential for a significant inflammatory response. Studies in rabbits revealed heavy leukocyte infiltration of arteries treated with empty adenoviral vectors, as well as vectors carrying a marker gene. 38 This inflammatory response was associated with a dramatic increase in IH. In our studies, minimal inflammation was detected with either AdiNOS or AdlacZ. An explanation for this difference lies with the titer of adenoviral vector that we used. The inflammatory changes in the above-mentioned study were associated with use of adenoviral vectors at concentrations of 2 × 10 10 pfu. Our experiments were performed with viral concentrations 20-fold lower than that inflammatory threshold. The ability to reduce IH with such low titers of AdiNOS is an attractive feature of iNOS that stems from its high enzymatic-specific activity and the diffusible quality of NO.
The future of iNOS gene transfer is promising. We have now shown that adenoviral-mediated iNOS gene transfer is beneficial in three different forms of vascular disease: arterial injury, transplant vasculopathy, and now vein graft IH. Although a number of gene therapy approaches with other genes are currently being studied, iNOS-based therapy may be one of the most attractive.
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